MethylPREDNISolone Dose Pack Alternatives Compared
| MethylPREDNISolone Dose Pack (methylprednisolone) | Xolair (omalizumab) | Montelukast |
|
|---|
| MethylPREDNISolone Dose Pack (methylprednisolone) | Xolair (omalizumab) | Montelukast |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Asthma, Allergic Rhinitis, Asthma - Maintenance, Asthma - acute, Congenital Adrenal Hyperplasia, Atopic Dermatitis, Dermatologic Lesion, Gout - Acute, Immunosuppression, Inflammatory... View more |
Prescription only
Xolair is an injectable preparation that works by preventing IgE from binding to IgE receptors on mast cells and basophils and may be used to treat allergic asthma, nasal polyps, chronic idiopathic... View more |
Prescription only
Montelukast is an oral medication that is usually taken daily for the maintenance treatment of asthma or allergic rhinitis. It will not relieve an acute asthma attack and some people may experience... View more |
Related suggestions Asthma, Maintenance
Popular comparisons
|
|||||||||||||||
| More about MethylPREDNISolone Dose Pack (methylprednisolone) | More about Xolair (omalizumab) | More about Montelukast | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
MethylPREDNISolone Dose Pack has an average rating of 8.3 out of 10 from a total of 50 ratings on Drugs.com. 78% of reviewers reported a positive effect, while 10% reported a negative effect. |
Xolair has an average rating of 7.5 out of 10 from a total of 229 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 18% reported a negative effect. |
Montelukast has an average rating of 5.6 out of 10 from a total of 571 ratings on Drugs.com. 42% of reviewers reported a positive effect, while 41% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Xolair side effects |
View all Montelukast side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
| Lower cost generic approved |
N/A |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all MethylPREDNISolone Dose Pack prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Montelukast prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other methylprednisolone brands include: Depo-Medrol, Medrol, Medrol Dosepak, Solu-Medrol | Other omalizumab brands include: Omlyclo | Singulair | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
3.5 hours |
624 hours |
5.5 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
Excluding First Trimester
Category D
Positive evidence of risk
First Trimester See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 625 drugs are known to interact with MethylPREDNISolone Dose Pack:
|
A total of 29 drugs are known to interact with Xolair:
|
A total of 116 drugs are known to interact with Montelukast:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
|
||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
June 20, 2003 |
N/A |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.